Online inquiry

IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ655MR)

This product GTTS-WQ655MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AOC3 gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001277731.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8639
UniProt ID Q16853
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ655MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9780MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ3799MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ12557MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ6781MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ15599MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ12187MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ7519MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ14342MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW